The MoA was signed by Dr. Tham Seng Kong, Group Chief Executive Officer of ALPS Group; and Tan Sri Dato’ Sri Dr. Chin Yung Kong, Group Chairman and Chief Executive Officer of QMIS Financial Group; and was witnessed by Datuk Iskandar Mohd. Nuli, Executive Chairman of Labuan International Business & Financial Centre. The signing, which took place on June 2, 2022, was also witnessed virtually by the board of directors and shareholders of ALPS.

Commenting after the signing ceremony, Dr Tham Seng Kong said, “We are grateful to have the trust and support of QMIS, which signals confidence in ALPS’ performance. We are confident that the listing exercise will provide cheaper accessibility to predictive and precision healthcare management solutions to the public at large.”
 
Additionally, Tan Sri Dato’ Sri Dr. Chin Yung Kong said, “We are pleased to be given the opportunity to play a key role in enabling a new biotechnology firm such as ALPS to be listed on the NASDAQ. With the relevant growth strategies in place, we are confident that this IPO will strengthen ALPS’ financial position as it embarks upon the next phase of its business expansion.”

With this funding exercise, ALPS is poised to become the first biotechnology company in Southeast Asia to achieve unicorn status. ALPS hopes to drive the next phase in health management by utilising its technology and know-how in genetics sequencing, advance precision medicine and cellular therapy.